Shots:

• The approval is based on P-II KEYNOTE-629 study assessing Keytruda (200mg- IV- q3w) in 105 patients with recurrent or metastatic cSCC that is not curable by surgery or radiation
•  Results: ORR (34%); CR (4%) PR (31%); 69% had ongoing responses of six months or longer- @ follow-up time of 9.5mos. DOR has not reached
• Keytruda is an anti-PD-1 therapy- acts by increasing the ability of the body’s immune system to help detect and fight tumor cells. The approval marks the first indication for Keytruda in cSCC

Click here to read full press release/ article 

Ref: Businesswire | Image: Merck